3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Ben Jawdat of Revterra, Pete O'Heeron of FibroBiologics, and Jay Manouchehri of Fluence Analytics. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to clean energy — recently making headlines in Houston innovation.

Ben Jawdat, CEO and founder of Revterra

Ben Jawdat, CEO and founder of Revterra, joins the Houston Innovators Podcast. Photo via LinkedIn

Ben Jawdat founded Revterra in Houston based on a unique kinetic energy storage technology. The company has created away to better optimize existing grid-based electric vehicle charging ports while still minimizing a carbon footprint. The startup hopes to be a major player within the energy transition.

"We really want to be an enabling technology in the renewable energy transition," Jawdat says. "One part of that is facilitating the development of large-scale, high-power, fast-charging networks. But, beyond that, we see this technology as a potential solution in other areas related to the clean energy transition."

He shares more about what's next for Revterra on the podcast. Read more and listen to the episode.

Pete O'Heeron, CEO and chairman of FibroBiologics

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release. Read more.

Jay Manouchehri, CEO of Fluence Analytics

Fluence Analytics has exited to a multinational Japanese engineering and software giant. Image via FluenceAnalytics.com

Yokogawa, which has its US operations based in Sugar Land, acquired Fluence Analytics Inc. in a deal announced last week. The terms of the deal were not disclosed and, effective immediately, the company operate as Yokogawa Fluence Analytics. Jay Manouchehri, who joined the company in 2022, will continue to serve as CEO of the entity.

“Combining forces with Yokogawa Electric enables us to capture the full value of our unique data sets, and we can't wait to deliver this added value to our customers," Manouchehri says in a news release. "Together, we will enable autonomous operations and digital transformation in the polymer and biopharma industries."

Founded in 2012 in New Orleans, Fluence Analytics moved to Houston in 2021 following a $7.5 million venture capital raise led by Yokogawa Electric Corp., which has its North American headquarters in Sugar Land. Read more.

From Your Site Articles
You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

Houston biopharma company launches equity crowdfunding campaign

money moves

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


This week's roundup of Houston innovators includes Allie Danziger of Ampersand Professionals, Pete O'Heeron of Fibrobiologics, and Brandy Guidry of The Cannon. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health innovation to job training technology — recently making headlines in Houston innovation.

Allie Danziger, founder and CEO of Ampersand Professionals

After working with thousands of interns, Allie Danziger of Ampersand Professionals says she's now got a product to upskill and train new hires for employers. Photo courtesy of Ampersand

Allie Danziger is taking the workforce development programming she's created for training and matching interns with businesses to a whole new level. The new offering gives companies an opportunity to streamline their onboarding process with Ampersand's plug-and-play programming.

Danziger says usually new hires need the most experienced mentor or manager, but they don't usually get that support — especially when it comes to businesses that don't have their own built-out mentorship or training program.

"Ampersand’s new training product fills that gap — it gives employers of any size any easy solution to provide basic job readiness training to employees, access to our team of dedicated coaches, and a detailed report at the end of their training summarizing how their new hire did in the training and any trends recognized and tips for managing this employee based on what the platform uncovered," she says. "Businesses can also sign up for additional coaching sessions and customize training materials, as an add-on if interested." Click here to read more.

Pete O'Heeron, CEO and chairman of FibroBiologics

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Fibroblasts have so much potential for a wide range of cell therapy treatments — the opportunities are endless, according to Pete O’Heeron, CEO, founder, and chairman of FiberBiologics, a Houston-based company that’s using fibroblast cell technology to treat a variety of chronic diseases.

With over 150 patents issued or pending, O'Heeron's team has the most intellectual property surrounding fibroblasts in the world and, while there is a lot of activity in the stem cell space, they are the leader when it comes to fibroblasts, he says. FiberBiologics is the name of the entity O'Heeron is hoping to take public by the end of the year, but the business originated as SpinalCyte, specializing in spinal treatment, before evolving into FibroGenesis as the technology began treating more parts of the body.

"With fibroblasts being the most common cell in the human body, you have to assume its involved in every process of the human body," O'Heeron says on last week's episode of the Houston Innovators Podcast. "There's literally not biological process in the body where fibroblasts are not involved." Click here to listen to the episode and read more.

​Brandy Guidry, Pearland navigator at The Cannon

The Pearland Innovation Hub celebrates its launch this month. Photo via pearlandinnovationhub.com

The Pearland Economic Development Corp. has launched the Pearland Innovation Hub, aimed at connecting small businesses with programs and services that are designed to contribute to their success.

The Pearland Innovation Hub is managed through a partnership between the Pearland Economic Development Corp. and The Cannon, a Houston-area business networking community for entrepreneurs, investors, and corporate innovators. For now, the hub does not officially have a physical space. The Cannon hired Brandy Guidry to run the Pearland hub. She has more than 17 years of experience in business operations; engineering; technical marketing; innovation; and strategic planning, project, and program management.

“The Pearland Innovation Hub is a groundbreaking initiative to support existing and aspiring small business owners,” Guidry adds. Click here to read more.


Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Houston cell therapy company prepares to IPO, move into new facility

Houston Innovators Podcast episode 135

Stem cells have had their time in the spotlight for a while, and now it's time for fibroblasts to have their moment, according to Pete O’Heeron, CEO, founder, and chairman of FibroBiologics, a Houston-based company that’s using fibroblast cell technology to treat a variety of chronic diseases.

The two types of cells are the only ones that can be used in cell therapy for a regenerative treatment, meaning that specialists can take healthy stem cells and fibroblasts from a patient and inject them into a part of the body that needs it the most. And, according to O'Heeron and his team, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron on this week's Houston Innovators Podcast. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."

With over 150 patents issued or pending, O'Heeron's team has the most intellectual property surrounding fibroblasts in the world and, while there is a lot of activity in the stem cell space, they are the leader when it comes to fibroblasts, he says. FibroBiologics is the name of the entity O'Heeron is hoping to take public by the end of the year, but the business originated as SpinalCyte, specializing in spinal treatment, before evolving into FibroGenesis as the technology began treating more parts of the body.

"With fibroblasts being the most common cell in the human body, you have to assume its involved in every process of the human body," O'Heeron says. "There's literally not biological process in the body where fibroblasts are not involved."

The strongest treatments under FibroBiologics's umbrella are for degenerative disc disease, orthopedics, multiple sclerosis, and cancer. With these applications progressing, O'Heeron has imminent IPO plans for the company.

"We're in the process of getting the company public so that we can have access to the resources to do larger scale human trials. So, I think over the next year you'll see us launch at least two large scale human trials with fibroblast with the intention of submitting to the FDA for commercialization," O'Heeron says.

The company is in the process of building out a new 14,000-square-foot-space that will allow FibroBiologics to house its office, lab, and manufacturing space under one roof for the first time.

"These are fantastic robust cells, and we want to be able to control the quality and potency of them and how they ship out and how we're able to transfer those cells to the end user," O'Heeron says.

He shares more about the company and the impact he expects fibroblasts to have on cell therapy treatment. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


This innovative health care company has announced some big moves. Photo via Fibrobiologics.com

Houston health care company raises $100M and plans to IPO

big moves

A clinical stage therapeutic company has made some big moves — with an even bigger one on the horizon.

FibroBiologics, which is developing fibroblast-based therapeutic cures for chronic diseases, announced $100 million in fresh funding resulting from an agreement with GEM Global Yield LLC SCS, a private investment group, with offices in New York and Paris. The funds will be distributed over a 36-month term following a public listing of FibroBiologics common stock.

According to a news release, "FibroBiologics will control the timing and maximum amount of the drawdown under this facility and has no minimum drawdown obligation." The IPO could include acquisition via SPAC.

"This Agreement with GEM helps secure additional funding to further develop cell therapy cures in Multiple Sclerosis, Degenerative Disc Disease and Cancer using fibroblast cells," says Pete O'Heeron, CEO and chairman of FibroBiologics, in the release. "This Agreement provides for a strong balance sheet upon public listing and positions FibroBiologics for the next stage of commercial development to deliver life-changing abatement for patients with incurable chronic diseases."

Founded earlier this year, FibroBiologics offices in Southeast Houston adjacent to the University of Houston-Clear Lake campus, where O'Heeron completed his Masters in Healthcare Administration.

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston humanoid robotics startup Persona AI hires new strategy leader

new hire

Houston-based Persona AI, a two-year-old startup that develops robots for heavy industry, has hired an automation and robotics professional as its head of commercial strategy.

In his new position, Michael Perry will focus on building Persona AI’s business development operations, coordinating with strategic partners and helping early adopters of the company’s humanoids. Target customers include offshore platforms, shipyards, steel mills and construction sites.

Perry previously served as vice president of business development at Boston Dynamics, where he led market identification for robotics, and as an executive at DJI. He holds a bachelor’s degree in Chinese and government studies from the University of Texas at Austin.

“Now is the perfect time to join Persona AI as we rapidly close the gap between what’s possible in the lab versus what’s driving real commercial value,” Perry says. “Building industry-hardened humanoid hardware and production-deployable AI is only one piece of the puzzle.”

“Getting humanoids into operations for heavy industry will require the systematic commercial and operational work that makes enterprises humanoid-ready and defining the business case, solving the integration challenges, and building the playbook for safe, scalable adoption,” he adds. “That’s what I’m here to build.”

Rice to lead Space Force tech institute under $8.1M agreement

space deal

Rice University has signed an $8.1 million cooperative agreement to lead the U.S. Space Force University Consortium/Space Strategic Technology Institute 4 (SSTI).

The new entity will be known as the Center for Advanced Space Sensing Technologies (CASST) at Rice and will focus on developing innovative remote sensing technologies.

“This investment positions Rice at the forefront of the technologies that will define how we see, understand and operate in space,” Amy Dittmar, Howard R. Hughes Provost and executive vice president for academic affairs, said in a news release. “By bringing together advanced remote sensing, AI-driven analysis and cross-institutional expertise, CASST will help transform raw space data into real-time insight and expand the frontiers of scientific discovery.

The news comes shortly after the Texas Space Commission approved a nearly $14.2 million grant for the newly created Center for Space Technologies at Rice.

David Alexander, director of the Rice Space Institute, will lead CASST. Alexander is also an inaugural member of the Texas Aerospace Research and Space Economy Consortium and he serves on the boards of the Houston Spaceport Development Corporation, SpaceCom and the Sasakawa International Center for Space Architecture. The team also includes Rice professors and staff Kevin Kelly, Tomasz Tkaczyk, Kenny Evans, Kaden Hazzard, Mark Jernigan and Vinod Veedu, and collaborators from Houston-based Aegis Aerospace, University of California, Los Angeles, University of California, Santa Barbara and Georgia Institute of Technology.

In addition to bringing new space sensor innovation, the team will also work to miniaturize sensors while developing and implementing low-resource fabrication techniques, according to Rice. The researchers will also utilize AI and machine learning to analyze sensor data.

The U.S. Space Force uses space sensors to provide real-time information about space environments and assess potential threats. CASST is the fourth Space Strategic Technology Institute established by the USSF.

“Rice has helped shape the modern era of space research, and CASST marks a bold step into what comes next,” David Sholl, executive vice president for research at Rice, said in a news release. “As space becomes more contested and more essential to daily life, the ability to rapidly sense, interpret and act on what’s happening beyond Earth is critical. This center brings together the materials, engineering and data science innovations needed to deliver that capability."

The USSF University Consortium works with academic teams to develop breakthrough technologies and speed their transition into real-world applications for the U.S. Space Force.

The recent Rice award is part of $16 million over about three years. The USSF also signed a cooperative agreement with the University of Arizona in February.

The consortium has also helped facilitate several technological and commercial transitions over the last two years, including a $36 million commercial contract awarded to Axiom by Texas A&M University's in-space operations team and a follow-on $6 million contract to Axiom to build on technology developed by the University of Texas.

Leading Houston energy ecosystem rebrands for next phase

new look

Houston-based Energytech Nexus has rebranded.

The cleantech founders community will now be known as Energytech Cypher. Organizers say the new name was inspired by the Arabic roots of the word cypher, ṣifr, which is also the root of the word zero.

"A cypher is a key that unlocks what's hidden," Nada Ahmed, co-founder and chief revenue officer of Energytech Cypher, said in a news release. "And zero? Zero is where every transformation begins, the leap from 0 to 1, from idea to reality, from potential to power. We decode the energy transition by connecting the right founders, the right capital, and the right corporate partners at the right time, because the most important journey in energy is the one that takes you from nothing to something."

Energytech Nexus has rebranded to Energytech Cypher.

Co-founder and CEO Jason Ethier says that the name change better reflects the organization's mission.

"The energy transition doesn't have a technology problem. It has a connection problem," Ehtier added in the release. "The right founders exist. The right investors exist. The right partners exist. What's been missing is the infrastructure to bring them together—to decode the complexity, remove the friction, and make sure the best technologies find the markets that need them. That's what this community has always done. Energytech Cypher is the name that finally says it."

Energytech Cypher, previously known as Energytech Nexus, was first launched in 2023 and has grown from a podcast to a 130-member ecosystem. It has supported startups including Capwell Services, Resollant, Syzygy Plasmonics, Hertha Metals, Solidec and many others.

It is known for its flagship programs like the Pilotathon, which connects founders with industry partners for pilot opportunities. The event debuted in 2024.

Energytech Cypher also launched its COPILOT Accelerator last year. The accelerator partners with Browning the Green Space, a nonprofit that promotes diversity, equity and inclusion (DEI) in the clean energy and climatech sectors. The inaugural cohort included two Houston-based startups and 12 others from around the U.S.

It also hosts programs like Liftoff, Energy Tech Market, lunch and learns, CEO roundtables, investor workshops and international partnership initiatives.

Last year, Energytech Cypher also announced a new strategic ecosystem partnership with Greentown Labs, aimed at accelerating growth for clean energy startups. It also named its global founding partners, including Houston-based operations such as Chevron Technology Ventures, Collide, Oxy Technology Ventures, and others from around the world.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

View All Listings